Education
About Us
Working with TipRanks
Follow Us
Orthocell Ltd (AU:OCC)
ASX:OCC
OCC Stock Chart & Stats
Day’s Range― - ―
52-Week RangeAU$0.35 - AU$1.79
Previous CloseN/A
Volume2.26M
Average Volume (3M)1.49M
Market Cap
AU$364.17M
Enterprise ValueAU$54.39M
Total Cash (Recent Filing)AU$19.62M
Total Debt (Recent Filing)AU$759.89K
Price to Earnings (P/E)―
Beta1.26
Next Earnings
Aug 28, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding241,976,240
10 Day Avg. Volume1,210,177
30 Day Avg. Volume1,490,660
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)48.64
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.32Price Target Upside-8.33% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering0
---
Orthocell Ltd News
PremiumCompany Announcements
Orthocell Secures US FDA Clearance for Remplir Nerve Repair Product
PremiumCompany Announcements
Orthocell Secures FDA Clearance for Remplir, Targets US Nerve Repair Market
PremiumCompany Announcements
Orthocell Limited Requests Trading Halt Pending FDA Clearance Announcement
PremiumCompany Announcements
Orthocell to Present at HealthInvest 2025, Updates on FDA Application
PremiumCompany Announcements
Orthocell Expands Striate+ Sales in Key European MarketsPremiumCompany Announcements
Orthocell Secures Singapore Regulatory Approval for Striate+
PremiumCompany Announcements
Orthocell Ltd Issues Unquoted Securities to Bolster Employee Retention
PremiumCompany Announcements
Orthocell Ltd Issues Unquoted Equity Securities to Boost Employee Incentives---
Options Prices
Currently, No data available
---
Ownership Overview
3.20% Insiders
―
Mutual Funds
― Other Institutional Investors
96.80% Public Companies and
Individual Investors
OCC FAQ
What was Orthocell Ltd’s price range in the past 12 months?
Orthocell Ltd lowest share price was AU$0.35 and its highest was AU$1.79 in the past 12 months.
What is Orthocell Ltd’s market cap?
Orthocell Ltd’s market cap is AU$364.17M.
When is Orthocell Ltd’s upcoming earnings report date?
Orthocell Ltd’s upcoming earnings report date is Aug 28, 2025 which is in 146 days.
How were Orthocell Ltd’s earnings last quarter?
Orthocell Ltd released its earnings results on Feb 24, 2025. The company reported -AU$0.006 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.006.
Is Orthocell Ltd overvalued?
According to Wall Street analysts Orthocell Ltd’s price is currently Overvalued.
Does Orthocell Ltd pay dividends?
Orthocell Ltd does not currently pay dividends.
What is Orthocell Ltd’s EPS estimate?
Orthocell Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Orthocell Ltd have?
Orthocell Ltd has 241,976,240 shares outstanding.
What happened to Orthocell Ltd’s price movement after its last earnings report?
Orthocell Ltd reported an EPS of -AU$0.006 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.383%.
Which hedge fund is a major shareholder of Orthocell Ltd?
Currently, no hedge funds are holding shares in AU:OCC
---
Orthocell Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$1.32 (-8.33% Downside)
AU$1.32 (-8.33% Downside)
Blogger Sentiment
Bullish
AU:OCC Sentiment 98%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth AU$100.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
272.72%
12-Months-Change
Fundamentals
Return on Equity
-29.77%
Trailing 12-Months
Asset Growth
60.70%
Trailing 12-Months
Company Description
Orthocell Ltd
Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia. The company offers CelGro, a naturally derived collagen medical device for use in multiple indications to augment the surgical repair of bone, peripheral nerves, tendons, and cartilage; and Ortho-ATI, a cell therapy for treatment of chronic tendon injuries. It also provides Ortho-ACI, an autologous chondrocyte implantation to treat articular cartilage defects in the knee and ankle; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental application; and Remplir, a collagen scaffold used in peripheral nerve repair. Orthocell Limited was incorporated in 2006 and is headquartered in Murdoch, Australia.
---
OCC Stock 12 Month Forecast
Average Price Target
AU$1.32
▼(-8.33% Downside)
Technical Analysis
Biotron Limited
―
PYC Therapeutics Limited
―
Race Oncology Ltd.
―
Proteomics International Laboratories Ltd.
―
Control Bionics Ltd.
―
Best Analysts Covering OCC
1 Year
1 Year Success Rate
6/6 ratings generated profit
1 Year Average Return
+190.25%
reiterated a buy rating 5 months ago
Copying Tanushree Jain's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +190.25% per trade.
---